Navigation Links
Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018

Emerging Agents from Pfizer, AstraZeneca, GlaxoSmithKline, Bayer/Onyx and Boehringer Ingelheim, and Increased Use of Existing Agents from Eli Lilly and Roche Will Drive Growth, According to a New Report from Decision Resources

WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of targeted agents as well as increased use of existing agents in the maintenance setting will drive the non-small-cell lung cancer (NSCLC) drug market to nearly triple from $3.5 billion in 2008 to almost $10 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Non-Small-Cell Lung Cancer finds that, through 2013, market growth will be driven by the launch of targeted agents such as Pfizer's figitumumab as a first-line treatment for advanced NSCLC as well as the emergence of AstraZeneca's Zactima, Bayer/Onyx's Nexavar and Boehringer Ingelheim's Tovok as second-line and subsequent-line options. Additionally, from 2013 to 2018, Roche/Chugai's Avastin -- which is already approved in the first-line setting for advanced disease -- and GlaxoSmithKline's MAGE-A3 will be approved as much-needed options in the adjuvant setting for NSCLC.

The market will be further driven by increased use of maintenance therapy involving premium-priced agents such as Eli Lilly's Alimta, OSI/Roche/Chugai's Tarceva, Avastin and figitumumab through 2018, according to the report. Although maintenance treatment has not been used to a high degree in NSCLC to date, recent Phase III clinical trial results indicate that there is a place for this practice in the treatment of advanced disease.

Owing to sales of Eli Lilly's Alimta and Gemzar, Roche/Chugai's Avastin and OSI/Roche/Chugai's Tarceva, Eli Lilly and Roche dominated the NSCLC landscape in 2008 as each company held approximately one-third of the overall market. By 2018, however, Eli Lilly's share will drop below 16 percent as a result of generic erosion of Alimta and Gemzar, while increased uptake of Avastin and Tarceva will enable Roche to retain 29 percent of overall market share. Additionally, owing to the uptake of figitumumab, Pfizer will hold 23 percent of the overall NSCLC market in 2018.

"Despite the anticipated sales growth of the non-small-cell lung cancer therapy market, treatment will continue to be defined by only modest improvements in overall survival and response rate and the disease will continue to be characterized by substantial unmet needs," said Decision Resources Analyst Janie Mackay, Ph.D. "Opportunity remains for the development of an agent that provides a significant improvement in efficacy over current and emerging therapies, particularly in the early stages of non-small-cell lung cancer."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

          All company, brand, or product names contained in this document
           may be trademarks or registered trademarks of their respective

    For more information, contact:

    Decision Resources                  Decision Resources, Inc.
    Christopher Comfort                 Elizabeth Marshall
    781-296-2597                        781-296-2563   

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. Launches Advertising Program on China Central Television (CCTV) for its Xuelian Chongcao Oral Liquid
2. Medicsight Launches ColonCAD(TM) Online CTC Platform
3. Prometheus Launches MyCeliacID(TM), the First Do it Yourself, Saliva-Based Genetic Test Dedicated to Celiac Disease
4. Jackson International Launches New Website in Collaboration with Medicaview International
5. NRPA Launches "Parks Build Community"
6. The Time To Rethink Male Circumcision Is Now, Group Says In Launching
7. Intact America Launches Campaign to Change How America Thinks About Male Circumcision
8. Social Security Institute Launches the National Obamacare Opt Out (NOOO!) Registry
9. Progresso(R) to Launch New High Fiber Soup Line in Fall 2009
10. Egglands Best and Award-Winning Fitness Trainer Cathe Friedrich Launch National Health and Fitness Program
11. Hypoallergenic Cat Company Launches Pet Buddies Program to Donate Its Unique Kittens to Pet-Allergic Children Undergoing Long-Term Medical Treatment
Post Your Comments:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... launched their Black Friday sale a week early, offering 40% off select bras ... the intimate apparel industry through both mobile fit technology and the latest fashion, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy ... , FDA has long asserted that design and manufacture of Laboratory Developed ... and do not meet the device regulations. , Come up short in an inspection ...
(Date:11/24/2015)... ... 2015 , ... United Benefit Advisors (UBA), the nation’s leading ... its newest Partner Firm. Based in Jefferson City, Missouri, their core philosophy is ... of whether that client is a business, a family, or an individual. ...
(Date:11/24/2015)... ... November 24, 2015 , ... With Thanksgiving right around the corner, holiday travel ... help protect your family and vehicle. , According to the National Highway Traffic Safety ... Amica is sharing the following safety tips from the NHTSA: , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Diego -based Imprimis Pharmaceuticals, Inc. (NASDAQ: ... development, production and dispensing of novel compounded pharmaceuticals.  ... segments including ophthalmology, urology, sinus and integrative medicine.  ... from four facilities located in California ... New Jersey and Pennsylvania.  For ...
(Date:11/24/2015)... Nov. 24, 2015  Freudenberg Medical has developed specialty tubing ... outside of medical facilities. Africa ... care is sparse. Nevertheless, prompt diagnosis is important to treat ... the virus. With the help of a portable mini-lab or ... to village in affected areas and perform rapid testing for ...
(Date:11/24/2015)... , Nov. 24, 2015   Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform to ... and stroke, today announced that the Company,s Chief Executive ... the Piper Jaffray 27 th Annual Healthcare Conference ... at the New York Palace hotel in ...
Breaking Medicine Technology: